Linerixibat (Lynavoy)
26 May 2026
No Comments
Linerixibat is an orally administered, minimally absorbed ileal bile acid transporter (IBAT)
Issue: Vol. 44
The data beneath the disruption: why process maturity and data accountability will determine who is ready for what comes next
26 May 2026
No Comments
Regulatory information management (RIM) has been transformed over the past decade. Most organisations by
Europe’s Critical Medicines Act: A Test of Health Sovereignty—and Industrial Resolve
26 May 2026
No Comments
For three decades, Europe has steadily shifted the production of widely used medicines—and their
Empowering the Full Lifecycle of Drug Development
26 May 2026
No Comments
We accelerate pharmaceutical innovation to enable earlier access to good medicines In modern pharmaceutical
The Renaissance and Industrial (r)Evolution of Peptide and Oligonucleotide Therapeutics
26 May 2026
No Comments
What do you get when the Renaissance, Industrial Revolution, and Evolution converge? Exactly what
Patentability of polymorphic compounds: an analysis based on recent EPO decisions
17 April 2026
No Comments
Introduction Polymorphism, defined as the capacity of a chemical substance to crystallize in more
Are patient outcomes getting lost in safety data complexity?
17 April 2026
No Comments
Proactivity around drug safety is assumed in life sciences, yet the reality of adverse
Pharma’s great data mess: shouldn’t IDMP have solved this by now?
17 April 2026
No Comments
The International Organization for Standardization’s (ISO) Identification of Medicinal Products (IDMP) standards for medicinal
Toll processing: Resilience amid chemical supply chain disruptions
17 April 2026
No Comments
The chemical supply chain has rarely faced a more sustained period of disruption than
Smarter safety stocks for a volatile world: Harnessing artificial intelligence and real-time data for resilient pharmaceutical supply chains
17 April 2026
No Comments
In the last few years geopolitics in the form of export controls, energy shocks,